1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Arrowhead’s Focus On Plozasiran Intensifies Competition With Ionis

Drug May Reach Market In 2025, After Olezarsen

 
• By Mandy Jackson

Arrowhead’s in-house, late-stage cardiovascular disease programs will center on triglyceride-lowering plozasiran while it seeks a partner to fund Phase III for cholesterol-reducing zodasiran.

London, UK. 3rd January 2024. Horse racing events in the UK.
Targeting APOC3 is a two-horse race in hypertriglyceridemia • Source: Shutterstock

Arrowhead Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. both aim to bring their first wholly owned drugs to market for the treatment of familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), with Ionis’s olezarsen in the leading position. But Arrowhead outlined a new plan to focus all of its late-stage cardiovascular disease development efforts on its FCS and SHTG drug plozasiran, which means the company will seek a partner to pursue Phase III development of its other late-stage cardiovascular candidate, zodasiran.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Boehringer Boss Talks Tariffs And State Of Play In The US

 
• By Kevin Grogan

The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.

Edgewise’s HCM Candidate May Provide Advantages Over BMS’s Camzyos

 
• By Joseph Haas

With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By Kevin Grogan

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Baxdrostat, AstraZeneca’s Next Big CVRM Bet

 
• By Kevin Grogan

The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.

More from Therapy Areas

PureTech Weighs Up Pros And Cons Of Going Private

 
• By Kevin Grogan

The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.

Vocal For ‘Glocal’: How Menarini Is Adapting To Outperform In The Asia Pacific

 
• By Anju Ghangurde

Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.

Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success

 
• By Alaric DeArment

The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.